N Engl J Med 2021 Apr 22
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Related Questions
The patient is treatment naïve and asymptomatic. She also has disease in the body (bone and liver metastases).
New comment by Medical Oncologist at British Columbia Cancer Agency ( September 22, 2021)
Thank you!
Completely agree with Dr. @Reva K. Basho. The role of intrathecal therapy in HR+HER2- disease does seem to be diminishing, and used only in certain centers for the...
Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan?
Can data from ASCENT be applied to patients with C...
New answer by Medical Oncologist at Sarah Cannon Research Institute (November 3, 2021)
The approval of sacituzumab has given us a powerful tool in our bag of options for TNBC. In the ASCENT trial, remember that treatment of physician’s choice (TPC) ch...
Given seemingly improved efficacy in ASCENT patients who had less prior treatment, would you consider use after only one prior agent rather than two? ...
New answer by Medical Oncologist at Sarah Cannon Research Institute (November 3, 2021)
Sacituzumab is approved for patients with metastatic TNBC that have received at least 2 prior lines. However, the FDA specifies only one of these lines needs to be for metasta...
Many of the patients on ASCENT trial were heavily pre-treated and require growth factors. With the day 1,8 treatment cycle, is there a way to minimize...
New comment by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty ( November 25, 2021)
3 to 4 days daily per week growth factors not user friendly. Especially if patients are driving a long distance. Not to mention the constant reminder of cancer and treatment a...
In patients with prior perioperative immunotherapy with early relapse, would re-introduction of immunotherapy be reasonable with high TMB?
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (June 22, 2022)
Atezolizumab was granted accelerated approval by FDA in March 2019 based on data from the phase 3 IMpassion130 trial which demonstrated a statistically significant benefit to ...
Specifically, how do you consider T-DXd use in setting of other antibody-drug conjugates (e.g. sacituzumab vedotin)? Are there any special considerati...
New answer by Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center (August 16, 2022)
I believe both T-DXd and sacituzumab-govitecan are equally reasonable options for hormone receptor-negative, Her 2-low breast cancer. I would individualize treatment based on ...
For example, if the primary breast tumor was HER2 IHC 1+, but a metastatic site was HER2 IHC 0, would you still recommend using T-DXd?
Will you chang...
New answer by Medical Oncologist at Karmanos Cancer Institute, Wayne State University (September 13, 2022)
Yes, if metastatic disease is HER2 low.
New answer by Medical Oncologist at VanDeusen Oncology Consulting (October 3, 2022)
I think this question can now be broadened out beyond TNBC to ER+Her2- metastatic disease. While in TNBC the evidence supports (I think) using sacituzumab prior to leaning on ...
Is there any data on the efficacy of T-Dxd after progression on sacituzumab govitecan?
Does your approach differ by hormone receptor status now that ...
New answer by Medical Oncologist at University of Utah (July 24, 2023)
Fam-trastuzumab deruxtecan (TDxd) and sacituzumab govitecan (SG) were and are being developed separately; in the course of their development, their paths collided leading to t...